Wire · opportunities
AbelZeta Gets FDA IND Clearance for Prizlon-cel in Large B-Cell Lymphoma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 August 2026 · Fusion42 review
AbelZeta secured FDA clearance of an IND for Prizlon-cel, a bispecific CAR-T therapy targeting CD20 and CD19 for large B-cell lymphoma, enabling US clinical development with consolidated global rights. The company plans a dual US trial strategy for both CAR-T naive second-line patients and harder-to-treat post-CAR-T third-line patients, aiming to address a $11 billion global CAR-T market.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
The FDA's decision to accept response rate as a primary endpoint in post-CAR-T lymphoma patients could speed your therapy’s US approval without a randomized trial. You need to watch for final trial design to position Prizlon-cel as a viable retreatment option where others falter.
◆ Coverage
2 sources · 17 Aug 2026
◆ Related on Wire
◆ Topics